Skip to Content

Tag: Apnimed


News

In brief: Sunrise acquisition, sleep apnea survey, standing letter, IV shortage

October 11, 2024HME News Staff

FRESNO, Calif. – Sunrise Medical has acquired Nuprodx, a California-based manufacturer of bathroom mobility products, including a patented shower tub slider system for mobility impaired users.   The acquisition strengthens Sunrise Medical’s portfolio by adding Nuprodx’s bathroom mobility solutions to its existing broad range of assistive mobility solutions.   “Nuprodx’s innovative bathroom mobility products perfectly align with our mission...

Apnimed, CPAP, Inogen, Sleep Apnea, Sunrise Medical, Walgreens


Read Full Articlered right arrow icon

News

Survey shows ‘devastating’ impact of sleep apnea

October 10, 2024HME News Staff

CAMBRIDGE, Mass. – Two-thirds of respondents said exhaustion from obstructive sleep apnea affects their ability to be present with loved ones, according to a new survey from Apnimed.  The company’s Sleep Health Inquiries on Needs and Emotions (SHINE), which surveyed 1,500 people living with OSA, found:  74% reported feeling worn out or exhausted from fatigue  67% reported fearing long-term health consequences  34% reported fearing...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Apnimed makes critical additions to C-suite 

January 22, 2024HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea and related disorders, has named Graham Goodrich as chief commercial officer and Ted Harding as chief human resources officer. The company says the additions to the C-suite are critical as the company prepares to launch AD109, a potential nighttime oral treatment currently in Phase 3. “We are thrilled to have attracted two...

Apnimed, Graham Goodrich, Obstructive Sleep Apnea (OSA), oral therapy, Ted Harding


Read Full Articlered right arrow icon

News

In brief: Medline’s appetite, Apnimed’s joint venture

November 21, 2023HME News Staff

NORTHFIELD, Ill. – Medline has launched a new Food Benefit Solution that allows Medicare Advantage and Managed Medicaid Organizations to offer locally sourced and fresh produce, healthy groceries and prepared meals – delivered directly to member homes – as an added supplemental benefit.  “Access to a food benefit can help members meet their nutritional needs, encourage healthier eating habits, and manage and prevent chronic diseases,” said Amy Rogers, BSN, RN,...

Apnimed, Medline


Read Full Articlered right arrow icon

Also Noted

Apnimed enters JV with Shionogi 

November 20, 2023HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea, has announced a joint venture with Shionogi & Co., a pharmaceutical company based in Japan, to develop therapies to treat OSA and other sleep disorders. The joint venture, Shionogi-Apnimed Sleep Science, combines Apnimed’s deep knowledge of OSA, highly experienced clinical-stage drug development team and robust network of...

Apnimed, Joint Venture, Obstructive Sleep Apnea (OSA)


Read Full Articlered right arrow icon

Also Noted

Apnimed appoints Yee as senior exec

September 20, 2023HME News Staff

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, has appointed John Yee, MD, MPH, as senior vice president of medical affairs. Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about the company’s lead drug candidate AD109, as well as other pipeline assets, as they progress through clinical development toward commercial launch....

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Apnimed secures additional financing 

January 3, 2023HME News Staff

CAMBRIDGE, Mass. – Apnimed has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The company will use proceeds to fund the planned Phase 3 trials for its lead candidate, AD 109 (aroxybutynin + atomoxetine), which has the potential to be the first oral treatment for obstructive sleep apnea. “This substantial additional investment is a significant vote of confidence by our investors,” said Larry Miller, M.D.,...

Apnimed, CPAP Alternative, Obstructive Sleep Apnea (OSA), oral therapy


Read Full Articlered right arrow icon

Also Noted

Apnimed looks forward to Phase 3 studies 

October 17, 2022HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, has announced positive topline results from the MARIPOSA Phase 2b trial – an efficacy, safety and dose-finding study of one-month duration. The results were positive for the company’s lead candidate for OSA, AD109 (atomoxetine + aroxybutynin). The primary endpoint showed a statistically significant...

Apnimed, Obstructive Sleep Apnea (OSA)


Read Full Articlered right arrow icon

Also Noted

Apnimed secures funding for OSA treatment

May 5, 2022HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Apnimed treatment shows reduction in AHI

November 17, 2021HME News Staff

CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182. Patients treated with AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in AHI from placebo, which...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon